Showing 51–75 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Thi Mai Phuong Nguyen, Van Luong Dinh, Binh Hoa Nguyen, Thi Thanh Thuy Hoang, Viet Nhung Nguyen, et al.
…in-resistant TB (RR-TB) burden country. Different new RR-TB regimens were recommended in recent years. Locally-generated evidence about nationwide implementation of different RR-TB regimens is essential to inform national treatment guidelines. **METHODS:** A retrospective cohort…
Yilin Zhang, Yang Li, Yuanyuan Chen, Cui Cai, Hengzhong Yi, et al.
…IVES:** Effective rifampicin-resistant tuberculosis (RR-TB) regimens often include multiple QT-prolonging drugs, necessitating evaluation across different combinations. **METHODS:** Using pooled electrocardiogram data from two trials, three QT-prolonging shorter regimens for RR-…
Hassane-Harouna S, Cherif GF, Ortuno-Gutierrez N, Cisse D, Camara LM, et al.
Setting Since August 2016, after the Ebola outbreak, the Guinean National Tuberculosis Programme and Damien Foundation implemented the shorter treatment regimen (STR) for multidrug-resistant tuberculosis (MDR-TB) in the three MDR-TB sites of Conakry. Previously, the longer regime…
Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, et al.
…und New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. F…
Ge Q, Ma Y, Zhang L, Ma L, Zhao C, et al.
…ate, adverse reaction rate, and recurrence rate between two regimens. Multivariate Cox regression model was used to identify the potential risk factors for recurrence after successful treatment with proportional hazards assumptions tested for all variables. Results A total of 381…
Xiaonan Geng, Fan Zhang, Ruichao Liu, Fuzhen Zhang, Ziwen Li, et al.
… and compare the effectiveness of different DR-TB treatment regimens and to assess their safety profiles based on the frequency of adverse events and drug-specific reactions. **METHODS:** We systematically searched PubMed, Web of Science, and Embase for relevant studies publishe…
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, et al.
…evelopers aware of both the important features of treatment regimens, and patient and programmatic needs at the country level. In view of recent ground-breaking advances in tuberculosis treatment, WHO has revised and updated these regimen profiles. We used a similar process as fo…
Wolfe A, Jadhav P, May A, Seymour S, Blanchard A, et al.
…d with each regimen. Overall, rifampin-containing shortened regimens are the preferred modality for LTBI treatment. A recent study in 2023 evaluated adherence and tolerance of the isoniazid(INH) + rifapentine(RPT), or "3HP" regimen and identified patient groups that may be at hig…
Kort F, Fournier Le Ray L, Chauffour A, Jarlier V, Lounis N, et al.
…nds supervising the treatment of tuberculosis. Intermittent regimens have the potential to simplify the supervision and improve compliance. Our objective was to analyse the sterilising activity of once-weekly regimens based on drugs with a long half-life, bedaquiline and rifapent…
Muniyandi M, Karikalan N, Velayutham B, Rajsekar K, Padmapriyadarsini C
Globally efforts are underway to shorten the existing 6-month tuberculosis (TB) treatment regimen for drug-sensitive patients, which would be equally effective and safe. At present, there is a lack of evidence on the cost implications of a shorter 4-month TB regimen in India. Thi…
Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, et al.
…s (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Markov model to estimat…
Mbelele PM, Mbelele PM, Mpolya EA, Sauli E, Mtafya B, et al.
…erculosis (RR/MDR-TB) treatment has largely transitioned to regimens free of the injectable aminoglycoside component, despite the drug class' purported bactericidal activity early in treatment. We tested whether Mycobacterium tuberculosis killing rates measured by tuberculosis mo…
Sulis G, Tavaziva G, Gore G, Benedetti A, Solomons R, et al.
…mide (2HRZE/10HR). The comparative effectiveness of shorter regimens is unknown. Methods To inform a WHO guideline update, we undertook a systematic review and meta-analysis to evaluate outcomes from regimens of 6- to less than 12-months' duration that included, at a minimum, iso…
Musisi E, Wyness A, Eldirdiri S, Dombay E, Mtafya B, et al.
…andard-of-care and experimental anti-tuberculosis treatment regimens on the respiratory microbiome and implications for treatment outcomes. Methods In this retrospective study, we analysed the sputum microbiome of participants with tuberculosis treated with six experimental regim…
Feng Z, Miao Y, Peng Y, Sun F, Zhang Y, et al.
…. There is an urgent need to simplify and shorten treatment regimens to reduce interruption and adverse event rates, improve compliance, and reduce costs. Methods ORIENT is a multicenter, randomized controlled, open-label, phase II/III, non-inferiority trial involving DS-TB patie…
Lin YJ, Lin HC, Yang YF, Chen CY, Lu TH, et al.
…logical impact and cost-effectiveness of shorter antibiotic regimens in high tuberculosis (TB) burden regions of Taiwan. Methods This study combined the TB population dynamic model and cost-effectiveness analysis with local data to simulate the disease burdens, effectiveness and …
Zheng X, Gui X, Yao L, Ma J, He Y, et al.
… the capacity of the short-course approach to identify drug regimens that can shorten the treatment time for tuberculosis.
Gao L, Zhang H, Xin H, Liu J, Pan S, et al.
… Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly regimen) were initially designed to be evaluated for rural residents aged 50-69 years with LTBI in China.Due to the incre…
Soni H, Kumar-M P, Mishra S, Bellam BL, Singh H, et al.
…jective : To compare risk of hepatotoxicity between various regimens for reintroduction of antitubercular therapy (ATT) in patients with previous episode of ATT hepatitis. Methods : We searched various databases (PubMed, Embase, CENTRAL, Scopus, WoS and LILACS) for studies compar…
Singhal KK, Shinde M
…acceptability of ATT. The available "short-course treatment regimens" are still relatively long, thereby adversely affecting treatment compliance. There is a need for effective, safe, short and intensive regimens for TB which can reduce the treatment cost and adverse effects, the…
Wheeler C, Mohle-Boetani J
…16%) than among nonincarcerated persons (6%). We compared 2 regimens to treat LTBI in an adult prison population in California: 9 months of twice-weekly isoniazid (9H; previous standard of care) and 12 once-weekly doses of isoniazid and rifapentine (3HP; introduced in 2011). Meth…
Budak M, Via LE, Weiner DM, Barry CE 3rd, Nanda P, et al.
…nization has focused goals of shortening standard treatment regimens for TB in their End TB Strategy efforts, which aim to reduce TB-related deaths by 95% by 2035. For this purpose, many novel and promising combination antibiotics are being explored that have recently been discov…
Jindani A, Atwine D, Grint D, Bah B, Adams J, et al.
BACKGROUND: Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid and secure lung sterilization and may enable shorter tuberculosis treatment regimens. METHODS: We …
Rich ML, Khan U, Zeng C, LaHood A, Franke MF, et al.
…ness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited. OBJECTIVES: To report end-of-treatment outcomes for MDR/RR-TB patients from a 2015-2018 multi-country cohort that received a regimen consistent w…
Berg A, Clary J, Hanna D, Nuermberger E, Lenaerts A, et al.
…necessitating the development of new and improved treatment regimens. Nonclinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in the …